期刊文献+

B型钠尿肽与慢性心力衰竭患者临床预后的关系研究 被引量:18

Effect of B-type natriuretic peptide on clinical prognosis of patients with chronic heart failure
暂未订购
导出
摘要 目的探讨B型钠尿肽(BNP)对慢性心力衰竭(CHF)患者的临床诊断价值、心功能评价及危险分层的意义。方法入选CHF患者208例,参照美国纽约心功能分级,心功能Ⅰ级50例(1组);心功能Ⅱ级51例(2组);心功能Ⅲ级55例(3组);心功能Ⅳ级52例(4组)。血浆BNP水平测定用放射免疫法;LVEF用彩色多普勒超声心动诊断仪测定。结果 1~4组患者血浆BNP水平分别为(78.05±1 2.86)ng/L、(235.38±36.65)ng/L、(587.98±75.78)ng/L、(1203.87±189.96)ng/L,与1组比较,2、3、4组患者BNP水平随着心功能级别的递增而显著增加,差异有统计学意义(P<0.01);2、3、4组患者随着BNP水平的升高,LVEF、6 min步行距离逐渐下降,随着CHF程度的加重,年住院次数增加;随访2、3、4组患者5年病死率分别为0,18.18%,44.23%;5年死亡风险随BNP水平的升高或治疗后下降幅度不明显而增大(P<0.01);BNP对LVEF<50%的CHF患者诊断敏感性、特异性分别为82.35%、75.42%;ROC曲线下面积为0.90。结论血浆BNP对CHF患者有较好的临床诊断价值,是CHF患者死亡风险较准确的评价指标之一;CHF患者血浆BNP水平与LVEF、6 min步行距离呈负相关。 Objective To study the effect of B-type natriuretic peptide(BNP) on clinical diagnosis, cardiac function assessment and risk stratification of patients with congestive heart failure(CHF). Methods Two hundred and eight CHF patients were divided into grade 1 cardiac function group (group 1 ,n= 50),grade 2 cardiac function group(group 2 ,n= 51),grade 3 cardiac function group (group 3,n=55) and grade 4 cardiac function group(group 4,n=52) according to the cardiac function grading recommended by NYHA. Their plasma BNP level was measured by radioimmunoassay and LVEF was detected by color Doppler echocardiography. Results The plasma BNP level was 78.05±12.86 ng/L,235. 38±36. 65 ng/L,587. 98±75. 78 ng/L and 1203.87±189.96 ng/L,respectively,in groups 1-4,which was significantly higher in groups 2-4 than in group 1 (P〈0.01). The LVEF and 6-minute walk test(6MWT) distance decreased gradually with the in- creasing BNP level in CHF patients. The times of patients admitted to hospital increased with the severity of heart failure in groups 2-4. The 5-year death rate of groups 2-4 was 0% ,18. 18%,and 44.23% ,respectively,during the f011ow-up period and the 5-year death risk increased with the increased BNP level or the insignificantly deceased BNP level after treatment(P%0.01). The sensitivity and specificity of BNP in CHF patients with their LVEF%50% were 82.35% and 75.42%, respectively. Conclusion Plasma BNP level is a rather good indication for the diagnosis of CHF and negatively related with the LVEF and 6MWT distance in CHF patients.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2012年第4期343-346,共4页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 利钠肽 心力衰竭 每搏输出量 超声心动描记术 预后 natriuretic peptide, brain heart failure stroke volume echocardiography prognosis
  • 相关文献

参考文献16

  • 1American Heart Association ACC/AHA. 2008 guideline for the management of adults with congenital heart disease[J].Journal of the American College of Cardiology,2008.143-263.
  • 2ESC. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008[J].European Heart Journal,2008.2388-2442.
  • 3Severo M,Pereira M,Bettencourt P. B-type natriuretic peptide measured in serum calibration using plasma samples for research purposes[J].Clinica y Laboratorio,2011.1015-1019.
  • 4Hill SA,Balion CM,Santaguida P. Evidence for the use of B type natriuretic peptides for screening asymptomatic populations and diagnosis in primary care[J].Clinical Biochemistry,2008.240-249.
  • 5Camillo JR,Borzaak R,Hennekens CH. Brain natriuretic peptide:Clinical and research challenges[J].Journal of Cardiovascular Pharmacology and therapeutics,2007.85-88.
  • 6Efremidis M,Pappas L,Sideris A. Management of atrial fibrillation in patients with heart failure[J].Journal of Cardiac Failure,2008.232-237.
  • 7Cowie MR,Jourdain P,Maise1 A. Clinical applications of B-type natriuretic peptide (BNP) testing[J].Eur Hcart,2003.1710-1718.
  • 8Beleigoli A,Diniz M,Nunes M. Reduced brain natriuretic peptide levels in class Ⅲ obesity:The role of metabolic and cardiovascular factors[J].Obes Facts,2011.427-432.
  • 9Jourdain P,Funck F,Bellorini M. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure[J].Ear J Heart Fail,2003.155-160.
  • 10Betli I,Caotelli G,Barchielli A. The role of N-terminal pro brains natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure:The PROBE-HF study[J].Cardic Failure,2009.377-384.

同被引文献137

  • 1邵春来,洪小苏.脑利钠肽与心血管疾病的研究进展[J].心血管病学进展,2005,26(1):36-40. 被引量:20
  • 2田颖,祝善俊,王江.神经内分泌拮抗治疗慢性心力衰竭的几个热点问题[J].中华心血管病杂志,2005,33(5):485-488. 被引量:42
  • 3余国膺.欧洲心脏学会修订心力衰竭指南[J].中国心脏起搏与心电生理杂志,2005,19(4):315-315. 被引量:4
  • 4心肌病诊断与治疗建议[J].中华心血管病杂志,2007,35(1):5-16. 被引量:568
  • 5戚文航.心力衰竭患者的心律失常治疗[c].中华医学会第十三次全国心血管病学术会议论文集.2011:13-14.
  • 6吴学思.欧美慢性心力衰竭2005诊疗指南特点[c].第八届中国南方国际心血管病学术会议.2006:127-129.
  • 7di Napoli,Taccardi AA,Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemie dilated cardiomyopothy. Heart, 2005,91 (2) : 161-165.
  • 8Babur GUler G,Karaahmet T, Tigen K. Myocardial fibrosis detected by cardiac magnetic resonance imaging in heart failure: impact on remodeling, diastolic function and BNP levels. Anadolu Kardiyol Derg, 2011,11 ( 1 ) : 71-76.
  • 9Udelson JE,Konstam MA.Ventricular remodeling fundamental to the progression (and regression) of heart failure. J Am Coll Cardiol,2011,57(13) : 1477-1479.
  • 10Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart dis ease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circula tion,2008,118(23) :e714-e833.

引证文献18

二级引证文献149

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部